Invention Grant
- Patent Title: NMDA receptor modulators and uses thereof
-
Application No.: US17585849Application Date: 2022-01-27
-
Publication No.: US11807650B2Publication Date: 2023-11-07
- Inventor: David R. Anderson , Robert Volkmann , Frank Menniti , Christopher Fanger , Yuelian Xu
- Applicant: Novartis AG
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- Agency: McCarter & English, LLP
- Agent Michael J. DeGrazia
- The original application number of the division: US16471880
- Main IPC: C07D513/04
- IPC: C07D513/04 ; C07D471/04 ; C07D487/04 ; C07D495/04 ; C07D498/04 ; C07D513/20
Abstract:
Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.
Public/Granted literature
- US20220153755A1 NMDA RECEPTOR MODULATORS AND USES THEREOF Public/Granted day:2022-05-19
Information query
